Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penpulimab + Anrotinib in R/R cHL
NCT05683704Phase 2Enrolling by invitation
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Sep 2022
- Primary completion
- May 2024
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of penpulimab, anlotinib in classical Hodgkin lymphoma (cHL), sponsored by Tianjin Medical University Cancer Institute and Hospital. Started Sep 2022; status: enrolling by invitation.
02
Drugs
penpulimabanlotinib
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT05683704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05683704.